1	Small molecule biomarkers predictive of Chagas disease progression
2	
3	Zongyuan Liu ¹ , Steffany Vucetich ² , Kelly DeToy ² , Gustavo Durán Saucedo ³ , Manuela
4	Verastegui ⁴ , Paula Carballo-Jimenez ⁵ , Brandon N. Mercado-Saavedra ³ , Freddy Tinajeros ⁵ , Edith
5	S. Málaga-Machaca ⁴ , Rachel Marcus ⁶ , Robert H. Gilman ² , Natalie M. Bowman ^{7*} , Laura-Isobel
6	McCall ^{1,8*}
7	
8	1. Department of Chemistry and Biochemistry, University of Oklahoma, Norman, OK, USA
9	2. Department of International Health, Johns Hopkins Bloomberg School of Public Health,
10	Baltimore, MD, USA
11	3. Clinica de las Americas, Santa Cruz, Bolivia.
12	4. Infectious Diseases Research Laboratory, LID, Faculty of Sciences and Engineering,
13	Universidad Peruana Cayetano Heredia, Lima, Peru
14	5. IFHAD: Innovation For Health And Development, Prisma NGO, Lima, Perú
15	6. Medstar Union Memorial Hospital, Baltimore, MD, USA
16	7. Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC,
17	USA
18	8. Department of Chemistry & Biochemistry, San Diego State University, San Diego, CA, USA
19	
20	* Correspondence to: Natalie M. Bowman (natalie_bowman@med.unc.edu; clinical patient
21	cohort) or Laura-Isobel McCall (Imccall@sdsu.edu; overall study design and metabolomics)
22	
23	

24 Abstract

25 Chagas disease (CD) is a neglected tropical disease caused by the parasitic protozoan Trypanosoma cruzi. However, only 20% to 30% of infected individuals will progress to severe 26 27 symptomatic cardiac manifestations. Current treatments are benznidazole and nifurtimox, which 28 are poorly tolerated regimens. Developing a biomarker to determine the likelihood of patient 29 progression would be helpful for doctors to optimize patient treatment strategies. Such a biomarker 30 would also benefit drug discovery efforts and clinical trials. In this study, we combined untargeted 31 and targeted metabolomics to compare serum samples from T. cruzi-infected individuals who 32 progressed to severe cardiac disease, versus infected individuals who remained at the same disease 33 stage (non-progressors). We identified four unannotated biomarker candidates, which were 34 validated in an independent cohort using both untargeted and targeted analysis techniques. Overall, 35 our findings demonstrate that serum small molecules can predict CD progression, offering 36 potential for clinical monitoring.

37

38 Keywords

Chagas disease; *Trypanosoma cruzi*; disease progression; biomarkers; metabolomics; mass
spectrometry

41

43 Introduction

44 Chagas disease (CD), caused by Trypanosoma cruzi parasites, is a vector-borne illness with a wide geographic range, primarily endemic to rural areas but also found in urban settings across 45 46 Mexico, Central America, and South America This neglected tropical disease is continually 47 expanding its range and impact due to climate change and migration; with cases found as far as Japan¹. If untreated, *T. cruzi* infection is lifelong and can be life-threatening. CD can result in 48 49 various complications, including megaesophagus, megacolon, arrhythmias, apical aneurysms, 50 congestive heart failure, thromboembolism, and sudden death. Among these, Chagas 51 cardiomyopathy is the most severe manifestation of the disease. Up to 30% of chronically infected 52 people develop cardiac complications, while 10% develop digestive, neurological, or mixed 53 symptomatology 2 .

The primary diagnosis method in chronic CD is serology 3 . PCR detection can only 54 demonstrate failure to clear parasites, not treatment success, given its high rate of false negatives 55 56 ^{4–6}. Given these limitations, there have been considerable efforts made to identify alternative 57 markers of successful parasite clearance and/or disease progression. These strategies include detection of antibodies to specific parasite proteins or parasite glycotopes ^{7,8,9,10,11}, host protein 58 fragments ^{12,13}, coagulation factors ¹⁴, or evaluation of immune cell types ^{15,16}. A critical limitation 59 of all these approaches, however, is that they rely on parasite clearance as a measure of treatment 60 61 success and prognosis. However, the BENEFIT clinical trial demonstrated that, when treatment 62 is administered to patients with pre-existing cardiac abnormalities, parasite clearance is insufficient to prevent disease progression or mortality ¹⁷. Therefore, biomarkers that only measure 63 64 parasite clearance are insufficient to predict clinical outcomes.

65 Multiple protein biomarkers have been correlated with CD stage, though none yet have 66 proven useful in a clinical context. IFN- γ is essential for the control of *T. cruzi* infection in experimental models. Serum from patients with chronic Chagasic cardiomyopathy had relatively 67 high expression of IFN- γ compared to noncardiac or indeterminate CD patients ^{18,19}. A recent study 68 found that differences in the levels of 44 host proteins correlated with clinical progression. 69 70 Interestingly, while many of those proteins were immune-associated, several of them (ATP5IF1, B4GALT1, GMPR, ISM1, AGRP) were linked to human metabolism ²⁰. Other protein biomarkers 71 72 of CD severity (TNF α , brain natriuretic peptide (BNP), or the MMP-2/MMP-9 ratio, for example), 73 only differentiate between symptomatic and asymptomatic patients or between advanced and early 74 stages of cardiomyopathy, and may not be able to predict disease progression in asymptomatic individuals ^{21–24,25}. BNP is a very nonspecific marker of congestive heart failure and is therefore 75 unsuitable as an early biomarker ^{26,23}. 76

77 Serum and urine metabolites have been identified as indicators of T. cruzi infection status in human subjects and mouse models ^{27,28,29}. The level of cardiac acylcarnitines and 78 glycerophosphocholines were correlated with markers of cardiac inflammation and fibrosis ³⁰. 79 80 Furthermore, the cardiac metabolome could be used to predict infection outcome in acute mouse models of infection³¹. A recent study showed that some metabolites could be restored by treatment 81 82 with the antiparasitic nifurtimox ²⁸. However, studies of metabolites as biomarkers of CD progression are lacking, especially in humans. Therefore, we analyzed samples from a multiyear 83 84 cohort of T. cruzi-infected Bolivians, comparing CD patients who showed cardiac disease progression, to patients who remained asymptomatic, and found four metabolites to be promising 85 biomarker candidates. Two of these metabolites showed increased levels in infected progressors 86 87 at baseline compared to non progressors, while the other two were decreased in infected

progressors.. Given the significant adverse effects of antiparasitic drugs and intermittent drug
 shortages ³², biomarkers of disease progression could help target more effective screening and
 interventions towards those who would benefit from them the most.

91

92 **Results**

93 Study participants

94 To explore potential metabolite biomarkers of progression to more severe cardiac disease 95 in patients chronically infected with T. cruzi, we studied four groups: infected progressors (N=37), infected non-progressors (N=91), uninfected 'progressors' (patients with non Chagasic heart 96 97 failure ; N=3) and uninfected non-progressors (healthy controls; N=13) (see Methods). Infected patients were monitored over 3 years. Patients that showed no symptoms, normal 98 99 electrocardiogram (EKG) and normal echocardiograms were defined as stage A. Patients who 100 showed no symptoms but had abnormal EKG fitting specific criteria were defined as stage B. 101 Patients showing systolic dysfunction in echocardiogram (EF < 50) were defined as stage C or D. 102 If a patient progressed from stage A to B or B to C/D during the study, they were classified as 103 progressors, while the non-progressors were those that remained at stage A or B. Importantly, 104 samples were collected from progressors prior to disease advancement, so that any metabolic 105 changes identified in this study can serve as prospective biomarkers of disease progression. The 106 uninfected progressors group was used to evaluate whether the observed metabolite changes were 107 specific to chagasic cardiomyopathy or also found in nonchagasic pathologies.

We matched patients from the infected progressor group and patients from the infected
 non-progressor group by gender, initial disease stage and age difference smaller than 5 years (see

Methods). Patient serum samples were analyzed by HPLC-MS/MS for untargeted metabolomic
analysis as described in the methods section, using two different chromatography methods
(pHILIC and polar C18), and MS data acquisition in positive and negative mode. Samples were
from two separate shipments of different patients, serving as two separate cohorts.

114

Limited association of progressing vs non-progressing status and overall metabolome

115 In terms of the overall metabolite profile (both cohorts combined), as shown in Figure 1, 116 all four groups clustered with each other. There was no significant difference in overall 117 metabolome between groups in polar C18 datasets, except between infected non-progressors and 118 uninfected non-progressors in positive mode (p=0.048 and pseudo-F=2.128), reflecting the impact 119 of infection on the metabolome. For pHILIC chromatography in both polarities, there were 120 likewise significant differences in overall metabolome for infected non-progressors vs uninfected 121 non-progressors (p=0.006 and pseudo-F=3.815 for positive mode, p=0.012 and pseudo-F=3.920 122 for negative mode), as well as differences between infected progressors vs uninfected non-123 progressors (p=0.021 and pseudo-F=2.905 for positive mode, p=0.042 and pseudo-F=2.987 for 124 negative mode) (Table 1).

125

126



Figure 1. Limited overall differences in serum metabolite profile between uninfected non-129

- progressor group, uninfected progressor group, infected non-progressor group, and infected 130
- 131 progressor group from pHILIC and polar C18 separation in both positive mode and negative
- mode data. All four groups showed overlap. 132
- 133

135

134 Table 1. Limited differences in overall metabolism between the four different patient groups. DEDMANOVA pyclus with Ponjamini Hachbarg EDP correction Pold EDP corrected p<0.05

PERMANOVA p values	with Benjamini-Поспоегд	, FDR confection. Bold, FD.	R-conec	ieu p<0.03.
datasets	group 1	group 2	p	pseudo F
			value	
pHILIC in positive mode	infected non-progressors	infected progressors	0.3640	1.330964
	infected non- progressors	uninfected non- progressors	0.0120	3.846872
	infected non-progressors	uninfected progressors	0.8130	0.664337
	infected progressors	uninfected non- progressors	0.0120	2.904537
	infected progressors	uninfected progressors	0.8130	0.685083
	uninfected non- progressors	uninfected progressors	0.6285	1.021994
	infected non-progressors	infected progressors	0.941	0.586750

pHILIC in negative mode	infected non- progressors	uninfected non- progressors	0.018	3.937563
	infected non-progressors	uninfected progressors	0.941	0.590266
	infected progressors	uninfected non- progressors	0.030	2.987234
	infected progressors	uninfected progressors	0.941	0.442172
	uninfected non- progressors	uninfected progressors	0.648	1.113972
polar C18 in positive	infected non-progressors	infected progressors	0.526	1.129306
mode	infected non- progressors	uninfected non- progressors	0.048	2.128310
	infected non-progressors	uninfected progressors	0.931	0.741003
	infected progressors	uninfected non- progressors	0.117	1.707515
	infected progressors	uninfected progressors	0.931	0.642245
	uninfected non- progressors	uninfected progressors	0.931	0.674938
polar C18 in negative	infected non-progressors	infected progressors	0.4275	1.170979
mode	infected non-progressors	uninfected non- progressors	0.3480	1.528665
	infected non-progressors	uninfected progressors	0.4275	1.113128
	infected progressors	uninfected non- progressors	0.3570	1.364624
	infected progressors	uninfected progressors	0.4290	1.012039
	uninfected non- progressors	uninfected progressors	0.4290	1.037428

136

137 Interestingly, for negative mode pHILIC data, infected progressors were more divergent 138 from infected non-progressors than from uninfected non-progressors in terms of overall 139 metabolome. For the positive mode polar C18 dataset, the infected progressors vs uninfected non-140 progressors showed the largest difference compared to infected progressors vs infected non-

progressors and infected progressors vs uninfected progressors in terms of overall metabolome, indicating that infected progressors have a distinct serum metabolite profile compared to infected non-progressors and uninfected non-progressors. The smaller difference between infected progressors and uninfected progressors in terms of overall metabolome suggests that progressed heart disease could show similar predictive metabolite profiles, with the caveat that only few uninfected progressor samples were available in this study. There were no significant differences between inter-group overall metabolic distances in positive mode pHILIC and negative mode polar





150Figure 2. PCoA distances between different progression groups. All cohorts, sexes and ages151combined. P values are calculated by Mann-Whitney U test, two-sided, FDR-corrected, *: 1.00e-152 $02 , **: 1.00e-03 < <math>p \le 1.00e-02$, ***: 1.00e-04 < $p \le 1.00e-03$, ****: $p \le 1.00e-04$.153ns, non-significant.

154

156 Limited confounding impact of age and sex

We also assessed whether different sexes showed different metabolite profiles associated with disease progression. However, as shown in **Figure S1**, we found that all four datasets showed no differences in terms of overall metabolome between experimental groups in both male and female subjects.

Samples were selected to have equal age representation and sex representation between 161 162 groups. However, we performed multi-parameter PERMANOVA to test the interaction between 163 age and sex, to know whether sex and age effects reduced our statistical power or masked effects 164 of disease on the metabolites. Positive mode pHILIC and polar C18 datasets showed a significant effect of age but not sex. However, negative mode pHILIC showed a significant effect of sex and 165 166 age, and negative polar C18 showed no significant effect of sex or age (Table 2). Importantly, all 167 four datasets showed no significant interactions between disease progression status and gender or 168 age (Table 2, PERMANOVA p>0.05). These results indicate that the different ages of the subjects 169 are impacting the metabolome, but not confounding our interpretation of disease outcomes, so we 170 chose to not subset the dataset by age or sex and analyze all samples jointly.

datasets	statistical results	gender	age	CD status	gender & age	CD status & age	CD status & gender
positive	R ²	0.011559	0.016552	0.038838	0.005335	0.016831	0.019426
pHILIC	p value	0.062	0.017	0.006	0.659	0.792	0.567
negative	R ²	0.017923	0.023319	0.033940	0.006735	0.014676	0.012115
pHILIC	p value	0.012	0.007	0.041	0.375	0.869	0.963
positive	R ²	0.010340	0.017939	0.026836	0.007124	0.017459	0.017973
polar C18	p value	0.075	0.005	0.079	0.378	0.780	0.736
negative	R ²	0.010930	0.010042	0.026023	0.007260	0.018661	0.018322
polar C18	p value	0.055	0.102	0.102	0.375	0.687	0.714

Table 2. p values of multi-parameter PERMANOVA for interaction between gender, age and infection status. Bold, p<0.05.

174

175

Discovery of individual metabolites predictive of progression status

To enable biomarker discovery and validation in separate cohorts, we separated samples based on shipments into two cohorts. Cohort 1 was used to discover candidate biomarkers, with validation in cohort 2, and vice versa, using untargeted metabolomics data to discover candidates, which were subsequently validated by targeted parallel reaction monitoring (PRM) analysis (**Figure 3**).



181

Figure 3. Diagram of the cross-validation between different cohorts. For cohort 1, N=26
infected progressors, N=69 infected non-progressors, N=3 uninfected progressors, N=13
uninfected non-progressors. For cohort 2, N=11 infected progressors, N=22 infected non-progressors.
progressors.

187 Our discovery significance cutoff was uncorrected two-sided Mann-Whitney-Wilcoxon 188 p < 0.05 for infected progressors vs infected non-progressors. We made this choice to select the 189 broadest range of candidates in the inclusion list for targeted analysis and minimize false negatives. 190 Targeted analysis on the second cohort then serves as independent validation, to eliminate any false positives. We then assessed if metabolites that met this significance criterion showed the 191 192 same direction of changes in both cohorts, with no significance cutoff. Lastly, we performed ROC 193 analysis, with AUC > 0.65 to filter this inclusion list for PRM analysis. However, in positive mode polar C18 cohort 1 discovery analysis, following the AUC cutoff, no candidate remained. To 194 195 expand the inclusion list for targeted analysis, we therefore manually added four additional specific m/z based on the literature on CD pathogenesis, for evaluation in the validation cohort. 196

197 Specifically, given our prior findings on impacts of infection on glycerophosphocholines and 198 purines ³³, we manually selected m/z 482.361 (lysophosphocholine O-16:0), m/z 137.046 199 (hypoxanthine), m/z 348.07 (adenosine diphosphate) and m/z 269.088 (xanthosine) to expand the 200 inclusion list. We also included these four candidates for validation analysis in cohort 1 (**Table 3**).

201 Biomarker candidate validation

202 Discovered candidate biomarkers were then validated in the reciprocal patient cohort using targeted analysis. Using this approach, we validated four biomarker candidates which showed 203 204 significant differences between infected progressors and infected non-progressors in the validation 205 cohort (**Table 3**). Two candidates came from the positive mode pHILIC dataset, and two from the negative mode pHILIC dataset. As shown in Figure 4 and Figure 5, m/z 547.436 RT (retention 206 207 time) 1.085 min from cohort 2 was validated by targeted analysis in cohort 1. m/z 540.411 RT 1.3 208 min from cohort 2 was validated by targeted analysis in cohort 1. m/z 295.14 RT 2.16 min and 209 m/z 493.39 RT 1.077 min, from negative mode pHILIC dataset in cohort 1 were validated by 210 targeted analysis in cohort 2. None of these metabolites had annotations.

Table 3. Candidate metabolite filtering and cross-validation. * means selection of extra
 candidates based on our current knowledge of CD, as described above.

cohort 1 discovery, cohort 2 valida	ation			
	positive pHILIC	negative pHILIC	positive pC18	negative pC18
discovered in cohort 1	308	439	7	11
validated in cohort 2 (untargeted)	3	1	0	1
inclusion list for PRM	3	1	4*	1
PRM validation in cohort 2	0	0	0	0
cohort 2 discovery, cohort 1 valida	ation			
	positive pHILIC	negative pHILIC	positive pC18	negative pC18
discovered in cohort 2	474	410	292	160
validated in cohort 1 (untargeted)	17	13	7	1
inclusion list for PRM	17	13	11*	1
PRM validation in cohort 1	2	2	0	0



214

215 Figure 4. Cross-validated biomarker candidates. (a) *m/z* 547.436 RT 1.085 min, from positive mode pHILIC dataset, initial discovery in cohort 2 (a1) and initial validation in cohort 1 (a2), 216 217 secondary validation in cohort 1 (a3). (b) m/z 540.411 RT 1.3 min, from positive mode pHILIC 218 dataset, initial discovery in cohort 2 (b1) and initial validation in cohort 1 (b2), secondary validation in cohort 1 (b3). (c) m/z 295.14 RT 2.16 min, from negative mode pHILIC dataset, 219 220 initial discovery in cohort 1 (c1) and initial validation in cohort 2 (c2), secondary validation in 221 cohort 2 (c3). (d) m/z 493.39 RT 1.077 min, from negative mode pHILIC dataset, initial discovery in cohort 1 (d1) and initial validation in cohort 2 (d2), secondary validation in cohort 2 (d3). All 222 223 four metabolites showed significant differences between infected progressors and infected nonprogressors. P values are calculated by Mann-Whitney U test, two-sided, no FDR-correction, *: 224 $1.00e-02 , **: <math>1.00e-03 , ***: <math>1.00e-04 , ****: <math>p \le 1.00e-03$, ****: $p \le 1.00e-03$, ***: $p \le 1.00e-03$, ****: $p \le 1.00e-03$, ***: $p \le 1.00e-03$, **: $p \ge 1.00e-03$, 225 226 1.00e-04. 227

228

_ _ _

229

231



Figure 5. Biomarker ROC curves. The AUC values for 547.436 RT 1.085 min and m/z 540.411
RT 1.3 min came from training in cohort 2 and predicted in cohort 1. The AUC values for m/z
295.14 RT 2.16 min and m/z 493.39 RT 1.077 min came from training in cohort 1 and predicted
in cohort 2.

237

232

238 Discussion

The ideal biomarker of CD should reflect disease progression, so that doctors can optimize interventions. There is currently no consensus on treatment of asymptomatic adults. Current CDC guidelines recommend treating asymptomatic *T. cruzi*-positive individuals 50 years or younger; treatment is optional for patients over 50 years old due to the high risk of side effects ¹⁰. The Pan American Health Organization (PAHO) recommends treatment in asymptomatic patients irrespective of age ³⁴, whereas the Brazilian Society of Cardiology sets an age cutoff similar to the

CDC ³⁵. This age range includes over a quarter of CD patients ^{36,3738} and most of the CD mortality ³⁹. 14% of adults treated with benznidazole, the preferred agent, will suspend treatment because of adverse effects ⁴⁰. A biomarker of disease progression could enable patients to make informed decisions with regards to the relative risks and benefits of treatment, enable assessment of treatment success, or inform clinical trial design.

250 Given prior work showing changes in circulating metabolites with T. cruzi infection in mouse models ^{29,41}, their association with disease severity in mouse models ^{30,42}, and infection-251 associated metabolite changes in human CD patients²⁸, we hypothesized that metabolite levels in 252 the serum of T. cruzi-infected individuals could predict CD progression. Overall metabolite 253 254 profiles between all four groups (infected progressors, infected non-progressors, uninfected 255 progressors and uninfected non-progressors) were very similar. Given that our discovery analysis 256 was being followed by a validation cohort, we chose to use looser criteria by not using FDR 257 correction for p-values in the discovery cohort. This decision led to low validation rates (Table 3), 258 but nevertheless enabled the discovery and validation of four candidate biomarkers at the 259 individual metabolite level. We also chose not to a priori exclude the biomarker candidates that 260 also showed significant differences between uninfected progressor and uninfected nonprogressors, because CD can be differentiated from non-CD heart disease through other means 261 (e.g. PCR, serodiagnosis ³). 262

263 One limitation for this project is patient comorbidities and behavioral differences that likely 264 increased variability. Multi-parameter PERMANOVA analysis showed that the different ages of 265 the subjects impact the metabolome, but did not confound our interpretation of disease outcomes 266 (**Table 2**). We therefore elected to analyse all samples jointly, without subsetting the dataset by 267 age or sex and for better statistical power given the limited sample numbers available. Likewise,

268 it is possible that some non-progressors will ultimately progress to symptomatic disease outside 269 this study's follow-up period, in which case our results may be interpreted as differentiating 270 between faster and slower progressors. Even given these limitations, we successfully validated 271 four biomarker candidates. m/z 547.436 RT 1.085 min and m/z 493.39 RT 1.077 min showed 272 decreased levels in infected progressors compared to infected non-progressors, while m/z 540.411 RT 1.3 min and *m/z* 295.14 RT 2.16 min showed increased level in infected progressors compared 273 274 to infected non-progressors. The lack of annotations for these biomarkers limits the biological 275 insight that can be derived from them. However, from a clinical implementation perspective, 276 annotations are not necessary for disease prediction. To enable cross-study assessment, we provide 277 m/z, retention time and MS/MS spectra, per the recommendations of the Metabolomics Standards Initiative ⁴³ (**Table S13**). Given the low parasite burden in chronic CD, these biomarkers are almost 278 279 certainly of host origin.

Further investigation in dogs and other animal models could be implemented to determine whether these biomarkers are common in mammals or only specific to humans. Canine biomarkers would be particularly useful given the high rates of CD in working dogs ⁴⁴. Assessment with a larger sample size is necessary for further validation, particularly with regards to patient and parasite genetic diversity. Evaluation of biomarker changes in response to treatment is also necessary.

286 Conclusion

We have identified four metabolite biomarkers that are predictive of progression to moresevere cardiac CD. These biomarkers show promise for use in human cohorts, either in the context

of evaluation of new therapeutic modalities, to prioritize treatment when drug availability islimited, or to increase treatment compliance in the highest-risk group.

291

292 Materials and methods

293 Study population

Serum samples were from the Johns Hopkins-Universidad Peruana Cayetano Heredia
Collaborated Studies Chagas disease biorepository, Johns Hopkins Institutional Review Board
(IRB) approval number IRB00007176. Initial sample collection was under Johns Hopkins
Institutional Review Board (IRB) approval number IRB00009799.

298 Samples were collected from Chagas disease patients and uninfected controls at the San 299 Juan de Dios Hospital, Santa Cruz, Bolivia (Table 4). As shown in Table 5, there were two 300 shipments from the study site, consisting of samples from different study participants. The first 301 shipment included all four groups but the second shipment only contained infected progressors 302 and infected non-progressors. The following staging criteria was used for determination of cardiac 303 progressors vs cardiac non progressors. Advanced stages C and D were determined by ejection 304 fraction (EF) on echocardiography. 40 < EF < 50 were designated stage C, regardless of EKG 305 results. EF <40 was designated stage D, regardless of EKG results. If EF >50, then the EKG results 306 were used to guide staging A vs B. To be classified as stage B, patients must present with at least 307 one of the following conditions: arrhythmias (including Afib/flutter, premature ventricular 308 contractions (PVCs) or ventricular tachycardia), bradycardia (heart rate <50), blocks (including 309 any AV Block, right bundle branch block, left bundle branch block, left anterior fascicular block, 310 non-specific intraventricular conduction delay, or bi or tri-fascicular blocks), pathologic O waves,

or paced rhythm. A normal EKG or any of the following abnormalities were determined to be stage
A: axis deviation, right ventricular hypertrophy/left ventricular hypertrophy, left atrial
enlargement/right atrial enlargement, low voltage, ST/T alterations, sinus tachycardia, long QT.
These criteria were developed to distinguish EKG changes specifically associated with Chagasic
cardiomyopathy as stage B.

317	Table 4. Number of subjects with sex and age information.

		gender		age			
groups		male	female	20-40	40-60	60-80	total
uninfected non-	cohort 1	10	3	3	7	3	13
progressors	cohort 2	0	0	0	0	0	0
uninfected	cohort 1	1	2	1	1	1	3
progressors	cohort 2	0	0	0	0	0	0
infected non-	cohort 1	52	17	10	43	16	69
progressors	cohort 2	12	10	1	9	12	22
infected	cohort 1	17	9	2	14	10	26
progressors	cohort 2	6	5	1	4	6	11

Table 5. Number of subjects by disease progression stage.

Groups		stage A	stage B	stage A to B	stage A to C/D	total
uninfected non-	cohort 1	13	0	0	0	13
progressors	cohort 2	0	0	0	0	0
uninfected	cohort 1	0	0	3	0	3
progressors	cohort 2	0	0	0	0	0
infected non-	cohort 1	69	0	0	0	69
progressors	cohort 2	22	0	0	0	22
infected	cohort 1	0	0	25	1	26
progressors	cohort 2	0	0	4	7	11

322 Serum sample preparation

Serum metabolites were extracted by adding equal volume of 100% methanol with 0.5 μM
sulfachloropyridazine (Fisher Optima) as internal standard, vortexed for 15 seconds, followed by
centrifugation at 14800 RPM for 15 minutes. The supernatant was collected into a 96-well plate,
then dried down by a speedvac overnight, as recommended in Dunn et al ⁴⁵. Dried sample plates
were stored at -80°C.

328 Untargeted LC-MS/MS data acquisition

Before LC-MS/MS instrumental analysis, dried extracts were resuspended with 80% acetonitrile (Fisher Optima; LC-MS grade), spiked with 2 μ M sulfadimethoxine (Sigma-Aldrich) as internal standard. Data acquisition was performed under the control of XCalibur and Tune software (ThermoScientific). Five pooled quality controls were injected at run start with injection volume 2 μ L, 3 μ L, 4 μ L, and 5 μ L to ensure system equilibration. Data was then acquired in randomized order, with a blank followed by a pooled quality control every 12 injections. The injection volume for each sample was 5 μ L.

A pHILIC LC column (SeQuant® ZIC®-pHILIC, 5 μm polymer, 150 x 2.1 mm) was used,
and the column was kept at 40°C during the run. Liquid chromatography was performed at 0.25
mL/min flow rate for 18 min. LC gradient was as follows, with mobile phase A (water with 20
mM ammonium acetate pH 9.4) and mobile phase B (acetonitrile): 0-10 min=90% B; 10-12
min=decrease to 30% B; 12-12.666 min=hold at 30% B; 12.666-18 min=increase to 90% B.

341 After the pHILIC LC-MS run, sample plates were dried down and resuspended with 100% 342 water (Fisher Optima; LC-MS grade), spiked with 2 μ M sulfadimethoxine (Sigma-Aldrich) as 343 internal standard. A Kinetex polar C18 LC column (Phenomenex; 50 × 2.1 mm, 1.7 μ M particle

size, 100 Å pore size) was used, and the column was kept at 40°C during the run. Liquid
chromatography was performed at 0.5 mL/min flow rate for 12.5 min. LC gradient was as follows,
with mobile phase A (water + 0.1% formic acid) and mobile phase B (acetonitrile +0.1% formic
acid): 0-1 min=5% B; 1-9 min=increase to 100% B; 9-11 min=hold at 100% B; 11-11.5=decrease
to 5% B; and 11.5-12.5=5% B. Mass spectrometry data acquisition parameters were the same as
pHILIC LC-MS run. In all cases, mass spectrometry data acquisition parameters were as

351 Targeted LC-MS/MS data acquisition

Resuspension procedure and LC columns were the same as for untargeted LC-MS/MS data acquisition, but mass spectrometry data acquisition was performed in parallel reaction monitoring (PRM) mode. Instrument parameters were the same as for untargeted LC-MS data acquisition. Inclusion lists are in **Tables S5-12**.

356 Data analysis

357 For untargeted analysis, collected data were analyzed through MZmine (version 2.53)⁴⁶ 358 with parameters as in **Table S14**. Data were filtered to retain features that were present in at least 359 two samples and had MS2 spectra to enable annotation. Blank removal was performed with a 360 minimum threefold difference between the blank and serum samples required for a feature to be 361 retained. Total ion current (TIC) normalization to a constant sum of 1 was performed in Jupyter 362 Notebook using R (version 3.6.1). MZmine output files were uploaded and analyzed by Featurebased molecular networking⁴⁷ in GNPS for annotation³³. Annotations were retrieved using a script 363 developed in our laboratory ⁴⁸. Lipid annotations such as glycerophosphocholines, 364 365 glycerophosphoethanolamines and acylcarnitines were further confirmed by searching the LIPID MAPS Structure Database (LMSD and COMPDB)^{49,50}. Feature tables combined with metadata 366

were analyzed in QIIME2⁵¹ for PCoA plot and distance analysis. Distances were compared using
Mann-Whitney-Wilcoxon test two-sided, FDR-corrected. PCoA plots were visualized in
EMPeror⁵². For further analysis, feature tables were filtered by the mass list which showed
significance between the infected progressed group vs infected non-progressed group. Jupyter
Notebook with Python (version 3.8.13) and R (version 3.6.1) were used for statistical analysis and
visualization.

373 To identify candidate biomarkers, we used Mann-Whitney-Wilcoxon test two-sided 374 without correction between infected progressors and infected non-progressors. This analysis 375 workflow minimizes false negatives. False positives are eliminated by analysis of an independent set of patients, in the targeted PRM analysis workflow (see below). Fold changes were calculated 376 377 to confirm that the direction of changes between infected progressors and infected non-progressors 378 were consistent between the two cohorts. We use ROC analysis and an AUC cutoff of 0.65 to 379 further evaluate the performance of the candidate biomarkers between infected progressors and 380 infected non-progressors in the different cohorts. ROC curves were created using scikit-learn 381 (version 1.3.0).

For PRM data analysis, collected data from the validation cohorts were analyzed through Skyline software (version 23.1) with parameters as in 27 . The exported peak areas were normalized by the peak area of the internal standard (*m/z* 311.0801 for positive mode and *m/z* 309.0656 for negative mode). Boxplot visualizations were made in Jupyter Notebook with Python (version 3.8.13) and R (version 3.6.1).

388 Data availability

- 389 The untargeted MS data generated in this study have been deposited in the MassIVE
- database for positive mode pHILIC: (MSV000092754),
- negative mode pHILIC (MSV000092756), positive mode polar C18 (MSV000092757), and
- negative mode polar C18 (MSV000092758). Feature-based molecular networking for untargeted
- 393 MS data can be accessed at:
- 394 <u>https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=ad84b5b572864898a733f159320bbd12</u>
- 395 (positive mode pHILIC),
- 396 <u>https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=7c725bc5bd23485dad48f5e3d6a5a84a</u>
- 397 (negative mode pHILIC),
- **398** <u>https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=73c7f72874d64fe78c9f97657df45bee</u>
- 399 (positive mode polar C18),
- 400 <u>https://gnps.ucsd.edu/ProteoSAFe/status.jsp?task=1e4c73cec97a4f09bbbd126da52a7262</u>
- 401 (negative mode polar C18). The targeted MS data for PRM validation have been deposited in the
- 402 MassIVE database for positive mode pHILIC (MSV000093740), negative mode pHILIC
- 403 (MSV000093741), positive mode polar C18: (MSV000093742), and negative mode polar C18
- 404 (MSV000093743). Representative code has been deposited on GitHub, at
- 405 <u>https://github.com/zyliu-OU/McCall-Lab/tree/main/05092023</u>.
- 406

407 Author Contributions

408	L-I.M. designed the proj	ject. Z.L. performed	l metabolite extraction,	LC-MS data
			,	

- 409 acquisition and LC-MS data analysis. Z.L. drafted the initial manuscript, which was edited by L-
- 410 I.M. with input from all authors. R.H.G. is the PI for the ongoing Bolivian cohort study which
- 411 provided the samples. R.H.G. and N.M.B. participated in study design, data interpretation, and
- 412 manuscript editing. K.D. and S.V. performed data management, cleaning, and staging for the
- 413 samples. G.D.S., M.V., P.C.J., B.M.S., F.T., E.M. and R.M. collected samples and patient data.

414 **Conflicts of interest**

415 The authors have no conflict of interest to declare.

416 Supporting Information

Figure S1. PCoA distances between different progression groups for male and female
participants. Table S1-S4. Annotation of differential metabolites. Table S5-S12. Skyline transition
lists. Table S13. MS2 spectra information for cross-validated biomarker candidates. Table S14.
MZmine data processing parameters table for all four datasets.

421 Acknowledgments

This project was supported by NIH award number R21AI156669. Samples were from the
Johns Hopkins-Universidad Peruana Cayetano Heredia Collaborated Studies Chagas disease
biorepository, with prior sample collection, clinical data collection and some salary support to
R.H.G and N.M.B. supported by NIH award number R01AI107028. The content is solely the

- 426 responsibility of the authors and does not necessarily represent the official views of the National
- 427 Institutes of Health.

428 Abbreviations used

- 429 CD, Chagas disease;
- 430 HILIC, Hydrophilic interaction chromatography;
- 431 LC-MS/MS, liquid chromatography-tandem mass spectrometry;
- 432 PRM, parallel reaction monitoring;
- 433 RT, retention time

434

435 **References**

- 436 (1) Moncayo, A. Chagas Disease: Current Epidemiological Trends after the Interruption of
- 437 Vectorial and Transfusional Transmission in the Southern Cone Countries. *Mem. Inst.*
- 438 *Oswaldo Cruz* **2003**, *98* (5), 577–591.
- 439 (2) Pinazo, M.-J.; Thomas, M.-C.; Bustamante, J.; Almeida, I. C. de; Lopez, M.-C.; Gascon, J.
- 440Biomarkers of Therapeutic Responses in Chronic Chagas Disease: State of the Art and
- 441 Future Perspectives. *Mem. Inst. Oswaldo Cruz* **2015**, *110* (3), 422–432.
- 442 (3) The Use of IgG Antibodies in Conventional and Non-Conventional Immunodiagnostic
- Tests for Early Prognosis after Treatment of Chagas Disease. J. Immunol. Methods 2011,
 370 (1-2), 24–34.
- 445 (4) Russomando, G.; Almirón, M.; Candia, N.; Franco, L.; Sánchez, Z.; de Guillen, I.
- 446 [Implementation and Evaluation of a Locally Sustainable System of Prenatal Diagnosis to
- 447 Detect Cases of Congenital Chagas Disease in Endemic Areas of Paraguay]. *Rev. Soc. Bras.*

448 *Med. Trop.* **2005**, *38 Suppl 2*, 49–54.

- 449 (5) Mora, M. C.; Negrette, O. S.; Marco, D.; Barrio, A.; Ciaccio, M.; Segura, M. A.;
- 450 Basombrío, M. A. EARLY DIAGNOSIS OF CONGENITAL TRYPANOSOMA CRUZI
- 451 INFECTION USING PCR, HEMOCULTURE, AND CAPILLARY CONCENTRATION,
- 452 AS COMPARED WITH DELAYED SEROLOGY. J. Parasitol. 2005, 91 (6), 1468–1473.
- 453 (6) Diez, C. N.; Manattini, S.; Zanuttini, J. C.; Bottasso, O.; Marcipar, I. The Value of
- 454 Molecular Studies for the Diagnosis of Congenital Chagas Disease in Northeastern

455 Argentina. Am. J. Trop. Med. Hyg. 2008, 78 (4).

456 (7) Krautz, G. M.; Galvão, L. M.; Cançado, J. R.; Guevara-Espinoza, A.; Ouaissi, A.; Krettli,

457 A. U. Use of a 24-Kilodalton Trypanosoma Cruzi Recombinant Protein to Monitor Cure of

458 Human Chagas' Disease. J. Clin. Microbiol. 1995. https://doi.org/10.1128/jcm.33.8.2086459 2090.1995.

- 460 (8) Meira, W. S. F.; Galvão, L. M. C.; Gontijo, E. D.; Machado-Coelho, G. L. L.; Norris, K. A.;
- 461 Chiari, E. Use of the Trypanosoma Cruzi Recombinant Complement Regulatory Protein To
- 462 Evaluate Therapeutic Efficacy Following Treatment of Chronic Chagasic Patients. J. Clin.

463 *Microbiol.* 2004. https://doi.org/10.1128/jcm.42.2.707-712.2004.

464 (9) Fernández-Villegas, A.; Pinazo, M. J.; Marañón, C.; Thomas, M. C.; Posada, E.; Carrilero,

465 B.; Segovia, M.; Gascon, J.; López, M. C. Short-Term Follow-up of Chagasic Patients after

- Benznidazole Treatment Using Multiple Serological Markers. *BMC Infect. Dis.* 2011, *11*
- **467** (1), 1–7.
- 468 (10) Montoya, A. L.; Carvajal, E. G.; Ortega-Rodriguez, U.; Estevao, I. L.; Ashmus, R. A.;
- 469 Jankuru, S. R.; Portillo, S.; Ellis, C. C.; Knight, C. D.; Alonso-Padilla, J.; Izquierdo, L.;
- 470 Pinazo, M.-J.; Gascon, J.; Suarez, V.; Watts, D. M.; Malo, I. R.; Ramsey, J. M.; Alarcón De

- 471 Noya, B.; Noya, O.; Almeida, I. C.; Michael, K. A Branched and Double Alpha-Gal-
- 472 Bearing Synthetic Neoglycoprotein as a Biomarker for Chagas Disease. *Molecules* **2022**, *27*
- 473 (17). https://doi.org/10.3390/molecules27175714.
- 474 (11) Montoya, A. L.; Gil, E. R.; Heydemann, E. L.; Estevao, I. L.; Luna, B. E.; Ellis, C. C.;
- 475 Jankuru, S. R.; Alarcón de Noya, B.; Noya, O.; Zago, M. P.; Almeida, I. C.; Michael, K.
- 476 Specific Recognition of β-Galactofuranose-Containing Glycans of Synthetic
- 477 Neoglycoproteins by Sera of Chronic Chagas Disease Patients. *Molecules* **2022**, *27* (2).
- 478 https://doi.org/10.3390/molecules27020411.
- 479 (12) Santamaria, C.; Chatelain, E.; Jackson, Y.; Miao, Q.; Ward, B. J.; Chappuis, F.; Ndao, M.
- 480 Serum Biomarkers Predictive of Cure in Chagas Disease Patients after Nifurtimox
- 481 Treatment. *BMC Infect. Dis.* **2014**, *14* (1), 1–12.
- 482 (13) Ruiz-Lancheros, E.; Rasoolizadeh, A.; Chatelain, E.; Garcia-Bournissen, F.; Moroni, S.;
- 483 Moscatelli, G.; Altcheh, J.; Ndao, M. Validation of Apolipoprotein A-1 and Fibronectin
- 484 Fragments as Markers of Parasitological Cure for Congenital Chagas Disease in Children
- 485 Treated With Benznidazole. *Open Forum Infect Dis* **2018**, *5* (11), ofy236.
- 486 (14) Pinazo, M.-J.; Posada, E. de J.; Izquierdo, L.; Tassies, D.; Marques, A.-F.; de Lazzari, E.;
- 487 Aldasoro, E.; Muñoz, J.; Abras, A.; Tebar, S.; Gallego, M.; de Almeida, I. C.; Reverter, J.-
- 488 C.; Gascon, J. Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease:
- 489 Potential Biomarkers of Therapeutic Response. *PLoS Negl. Trop. Dis.* **2016**, *10* (1),
- e0004269.
- 491 (15) Bustamante, J. M.; Bixby, L. M.; Tarleton, R. L. Drug-Induced Cure Drives Conversion to a
- 492 Stable and Protective CD8+ T Central Memory Response in Chronic Chagas Disease. *Nat.*
- 493 *Med.* **2008**, *14* (5), 542–550.

- 494 (16) Cesar, G.; Natale, M. A.; Albareda, M. C.; Alvarez, M. G.; Lococo, B.; De Rissio, A. M.;
- 495 Fernandez, M.; Castro Eiro, M. D.; Bertocchi, G.; White, B. E.; Zabaleta, F.; Viotti, R.;
- 496 Tarleton, R. L.; Laucella, S. A. B-Cell Responses in Chronic Chagas Disease: Waning of
- 497 Trypanosoma Cruzi-Specific Antibody-Secreting Cells Following Successful Etiological
- 498 Treatment. J. Infect. Dis. 2023, 227 (11), 1322–1332.
- 499 (17) Morillo, C. A.; Marin-Neto, J. A.; Avezum, A.; Sosa-Estani, S.; Rassi, A., Jr; Rosas, F.;
- 500 Villena, E.; Quiroz, R.; Bonilla, R.; Britto, C.; Guhl, F.; Velazquez, E.; Bonilla, L.; Meeks,
- 501 B.; Rao-Melacini, P.; Pogue, J.; Mattos, A.; Lazdins, J.; Rassi, A.; Connolly, S. J.; Yusuf,
- 502 S.; BENEFIT Investigators. Randomized Trial of Benznidazole for Chronic Chagas'
- 503 Cardiomyopathy. N. Engl. J. Med. 2015, 373 (14), 1295–1306.
- 504 (18) Poveda, C.; Fresno, M.; Gironès, N.; Martins-Filho, O. A.; Ramírez, J. D.; Santi-Rocca, J.;
- 505 Marin-Neto, J. A.; Morillo, C. A.; Rosas, F.; Guhl, F. Cytokine Profiling in Chagas Disease:
- 506 Towards Understanding the Association with Infecting Trypanosoma Cruzi Discrete Typing

507 Units (A BENEFIT TRIAL Sub-Study). *PLoS One* **2014**, *9* (3), e91154.

- 508 (19) Sousa, G. R.; Gomes, J. A. S.; Fares, R. C. G.; Damásio, M. P. de S.; Chaves, A. T.;
- 509 Ferreira, K. S.; Nunes, M. C. P.; Medeiros, N. I.; Valente, V. A. A.; Corrêa-Oliveira, R.;
- 510 Rocha, M. O. da C. Plasma Cytokine Expression Is Associated with Cardiac Morbidity in
- 511 Chagas Disease. *PLoS One* **2014**, *9* (3), e87082.
- 512 (20) Sunderraj, A.; Cunha, L. M.; Avila, M.; Alexandria, S.; Ferreira, A. M.; de Oliveira-da
- 513 Silva, L. C.; Ribeiro, A. L. P.; Nunes, M. do C. P.; Sabino, E. C.; Landay, A.; Kalil, J.;
- 514 Chevillard, C.; Cunha-Neto, E.; Feinstein, M. J. Parasite DNA and Markers of Decreased
- 515 Immune Activation Associate Prospectively with Cardiac Functional Decline over 10 Years
- among Trypanosoma Cruzi Seropositive Individuals in Brazil. Int. J. Mol. Sci. 2023, 25 (1),

- 518 (21) Ferreira, R. C.; Ianni, B. M.; Abel, L. C. J.; Buck, P.; Mady, C.; Kalil, J.; Cunha-Neto, E.
- 519 Increased Plasma Levels of Tumor Necrosis Factor-Alpha in
- 520 Asymptomatic/"indeterminate" and Chagas Disease Cardiomyopathy Patients. *Mem. Inst.*
- 521 *Oswaldo Cruz* 2003, *98* (3), 407–411.
- 522 (22) Lima-Costa, M. F.; Cesar, C. C.; Peixoto, S. V.; Ribeiro, A. L. P. Plasma B-Type
- 523 Natriuretic Peptide as a Predictor of Mortality in Community-Dwelling Older Adults with
- 524 Chagas Disease: 10-Year Follow-up of the Bambui Cohort Study of Aging. Am. J.
- 525 *Epidemiol.* **2010**, *172* (2), 190–196.
- 526 (23) Okamoto, E. E.; Sherbuk, J. E.; Clark, E. H.; Marks, M. A.; Gandarilla, O.; Galdos-
- 527 Cardenas, G.; Vasquez-Villar, A.; Choi, J.; Crawford, T. C.; Do, R. Q.; Fernandez, A. B.;
- 528 Colanzi, R.; Flores-Franco, J. L.; Gilman, R. H.; Bern, C.; Chagas Disease Working Group
- 529 in Bolivia and Peru. Biomarkers in Trypanosoma Cruzi-Infected and Uninfected Individuals
- 530 with Varying Severity of Cardiomyopathy in Santa Cruz, Bolivia. *PLoS Negl. Trop. Dis.*
- **2014**, *8* (10), e3227.
- 532 (24) Clark, E. H.; Marks, M. A.; Gilman, R. H.; Fernandez, A. B.; Crawford, T. C.; Samuels, A.
- 533 M.; Hidron, A. I.; Galdos-Cardenas, G.; Menacho-Mendez, G. S.; Bozo-Gutierrez, R. W.;
- 534 Martin, D. L.; Bern, C. Circulating Serum Markers and QRS Scar Score in Chagas
- 535 Cardiomyopathy. Am. J. Trop. Med. Hyg. 2015, 92 (1), 39–44.
- 536 (25) Sherbuk, J. E.; Okamoto, E. E.; Marks, M. A.; Fortuny, E.; Clark, E. H.; Galdos-Cardenas,
- 537 G.; Vasquez-Villar, A.; Fernandez, A. B.; Crawford, T. C.; Do, R. Q.; Flores-Franco, J. L.;
- 538 Colanzi, R.; Gilman, R. H.; Bern, C. Biomarkers and Mortality in Severe Chagas
- 539 Cardiomyopathy. *Glob. Heart* **2015**, *10* (3), 173–180.

^{517 44.}

- 540 (26) Weber, M.; Hamm, C. Role of B-Type Natriuretic Peptide (BNP) and NT-proBNP in
- 541 Clinical Routine. *Heart* **2006**, *92* (6), 843–849.
- 542 (27) Dean, D. A.; Roach, J.; vonBargen, R. U.; Xiong, Y.; Kane, S. S.; Klechka, L.; Wheeler, K.;
- 543 Sandoval, M. J.; Lesani, M.; Hossain, E.; Katemauswa, M.; Schaefer, M.; Harris, M.;
- 544 Barron, S.; Liu, Z.; Pan, C.; McCall, L.-I. Persistent Biofluid Small-Molecule Alterations
- 545 Induced by Trypanosoma Cruzi Infection Are Not Restored by Parasite Elimination. ACS
- 546 *Infectious Diseases* 2023. https://doi.org/10.1021/acsinfecdis.3c00261.
- 547 (28) Golizeh, M.; Nam, J.; Chatelain, E.; Jackson, Y.; Ohlund, L. B.; Rasoolizadeh, A.;
- 548 Camargo, F. V.; Mahrouche, L.; Furtos, A.; Sleno, L.; Ndao, M. New Metabolic Signature
- 549 for Chagas Disease Reveals Sex Steroid Perturbation in Humans and Mice. SSRN
- *Electronic Journal*. https://doi.org/10.2139/ssrn.4050413.
- 551 (29) Lizardo, K.; Ayyappan, J. P.; Ganapathi, U.; Dutra, W. O.; Qiu, Y.; Weiss, L. M.;
- Nagajyothi, J. F. Diet Alters Serum Metabolomic Profiling in the Mouse Model of Chronic
 Chagas Cardiomyopathy. *Dis. Markers* 2019, *2019*, 4956016.
- 554 (30) Hoffman, K.; Liu, Z.; Hossain, E.; Bottazzi, M. E.; Hotez, P. J.; Jones, K. M.; McCall, L.-I.
- Alterations to the Cardiac Metabolome Induced by Chronic Infection Relate to the Degree
 of Cardiac Pathology. *ACS Infect Dis* 2021, 7 (6), 1638–1649.
- 557 (31) McCall, L.-I.; Morton, J. T.; Bernatchez, J. A.; de Siqueira-Neto, J. L.; Knight, R.;
- Dorrestein, P. C.; McKerrow, J. H. Mass Spectrometry-Based Chemical Cartography of a
 Cardiac Parasitic Infection. *Anal. Chem.* 2017, *89* (19), 10414–10421.
- 560 (32) Viotti, R.; Vigliano, C.; Lococo, B.; Alvarez, M. G.; Petti, M.; Bertocchi, G.; Armenti, A.
- 561 Side Effects of Benznidazole as Treatment in Chronic Chagas Disease: Fears and Realities.
- 562 *Expert Rev. Anti. Infect. Ther.* **2009**, 7 (2), 157–163.

505 (55) LIU, Z., UITCH VOIDAIGEH, K., KEHUHCKS, A. L., WHEELEH, K., LEAO,
--

- 564 Sankaranarayanan, K.; Dean, D. A.; Kane, S. S.; Hossain, E.; Pollet, J.; Bottazzi, M. E.;
- 565 Hotez, P. J.; Jones, K. M.; McCall, L.-I. Localized Cardiac Small Molecule Trajectories and
- 566 Persistent Chemical Sequelae in Experimental Chagas Disease. *Nat. Commun.* **2023**, *14* (1),
- 567 1–22.
- (34) Organización Panamericana de la Salud. [Synthesis of evidence: Guidance for the diagnosis
 and treatment of Chagas diseaseSíntese de evidências: Guia de diagnóstico e tratamento da
 doença de Chagas]. *Rev. Panam. Salud Publica* 2020, *44*, e28.
- 571 (35) Marin-Neto, J. A.; Rassi, A., Jr; Oliveira, G. M. M.; Correia, L. C. L.; Ramos Júnior, A. N.;
- 572 Luquetti, A. O.; Hasslocher-Moreno, A. M.; Sousa, A. S. de; Paola, A. A. V. de; Sousa, A.
- 573 C. S.; Ribeiro, A. L. P.; Correia Filho, D.; Souza, D. do S. M. de; Cunha-Neto, E.; Ramires,
- 574 F. J. A.; Bacal, F.; Nunes, M. do C. P.; Martinelli Filho, M.; Scanavacca, M. I.; Saraiva, R.
- 575 M.; Oliveira Júnior, W. A. de; Lorga-Filho, A. M.; Guimarães, A. de J. B. de A.; Braga, A.
- 576 L. L.; Oliveira, A. S. de; Sarabanda, A. V. L.; Pinto, A. Y. das N.; Carmo, A. A. L. do;
- 577 Schmidt, A.; Costa, A. R. da; Ianni, B. M.; Markman Filho, B.; Rochitte, C. E.; Macêdo, C.
- 578 T.; Mady, C.; Chevillard, C.; Virgens, C. M. B. das; Castro, C. N. de; Britto, C. F. D. P. de
- 579 C.; Pisani, C.; Rassi, D. do C.; Sobral Filho, D. C.; Almeida, D. R. de; Bocchi, E. A.;
- 580 Mesquita, E. T.; Mendes, F. de S. N. S.; Gondim, F. T. P.; Silva, G. M. S. da; Peixoto, G. de
- 581 L.; Lima, G. G. de; Veloso, H. H.; Moreira, H. T.; Lopes, H. B.; Pinto, I. M. F.; Ferreira, J.
- 582 M. B. B.; Nunes, J. P. S.; Barreto-Filho, J. A. S.; Saraiva, J. F. K.; Lannes-Vieira, J.;
- 583 Oliveira, J. L. M.; Armaganijan, L. V.; Martins, L. C.; Sangenis, L. H. C.; Barbosa, M. P.
- 584 T.; Almeida-Santos, M. A.; Simões, M. V.; Yasuda, M. A. S.; Moreira, M. da C. V.;
- 585 Higuchi, M. de L.; Monteiro, M. R. de C. C.; Mediano, M. F. F.; Lima, M. M.; Oliveira, M.

- 586 T. de; Romano, M. M. D.; Araujo, N. N. S. L. de; Medeiros, P. de T. J.; Alves, R. V.;
- 587 Teixeira, R. A.; Pedrosa, R. C.; Aras Junior, R.; Torres, R. M.; Povoa, R. M. D. S.; Rassi, S.
- 588 G.; Alves, S. M. M.; Tavares, S. B. do N.; Palmeira, S. L.; Silva Júnior, T. L. da; Rodrigues,
- 589 T. da R.; Madrini Junior, V.; Brant, V. M. da C.; Dutra, W. O.; Dias, J. C. P. SBC Guideline
- on the Diagnosis and Treatment of Patients with Cardiomyopathy of Chagas Disease 2023.
- 591 *Arq. Bras. Cardiol.* **2023**, *120* (6), e20230269.
- 592 (36) Herrador, Z.; Rivas, E.; Gherasim, A.; Gomez-Barroso, D.; García, J.; Benito, A.; Aparicio,
- 593 P. Using Hospital Discharge Database to Characterize Chagas Disease Evolution in Spain:
- 594 There Is a Need for a Systematic Approach towards Disease Detection and Control. *PLoS*
- 595 *Negl. Trop. Dis.* **2015**, *9* (4), e0003710.
- 596 (37) de Oliveira-Marques, D. S.; Bonametti, A. M.; Matsuo, T.; Gregori Junior, F. The
- 597 Epidemiologic Profile and Prevalence of Cardiopathy in Trypanosoma Cruzi Infected Blood
- 598 Donor Candidates, Londrina, Paraná, Brazil. *Rev. Inst. Med. Trop. Sao Paulo* 2005, 47 (6),
 599 321–326.
- 600 (38) Meymandi, S. K.; Forsyth, C. J.; Soverow, J.; Hernandez, S.; Sanchez, D.; Montgomery, S.
- P.; Traina, M. Prevalence of Chagas Disease in the Latin American-Born Population of Los
 Angeles. *Clin. Infect. Dis.* 2017, *64* (9), 1182–1188.
- 603 (39) Herricks, J. R.; Hotez, P. J.; Wanga, V.; Coffeng, L. E.; Haagsma, J. A.; Basáñez, M.-G.;
- Buckle, G.; Budke, C. M.; Carabin, H.; Fèvre, E. M.; Fürst, T.; Halasa, Y. A.; King, C. H.;
- 605 Murdoch, M. E.; Ramaiah, K. D.; Shepard, D. S.; Stolk, W. A.; Undurraga, E. A.;
- 606 Stanaway, J. D.; Naghavi, M.; Murray, C. J. L. The Global Burden of Disease Study 2013:
- 607 What Does It Mean for the NTDs? *PLoS Negl. Trop. Dis.* **2017**, *11* (8), e0005424.
- 608 (40) Crespillo-Andújar, C.; Venanzi-Rullo, E.; López-Vélez, R.; Monge-Maillo, B.; Norman, F.;

- 609 López-Polín, A.; Pérez-Molina, J. A. Safety Profile of Benznidazole in the Treatment of
- 610 Chronic Chagas Disease: Experience of a Referral Centre and Systematic Literature Review
- 611 with Meta-Analysis. *Drug Saf.* **2018**, *41* (11), 1035–1048.
- 612 (41) Gironès, N.; Carbajosa, S.; Guerrero, N. A.; Poveda, C.; Chillón-Marinas, C.; Fresno, M.
- 613 Global Metabolomic Profiling of Acute Myocarditis Caused by Trypanosoma Cruzi
- 614 Infection. *PLoS Negl. Trop. Dis.* **2014**, *8* (11), e3337.
- 615 (42) Hossain, E.; Khanam, S.; Dean, D. A.; Wu, C.; Lostracco-Johnson, S.; Thomas, D.; Kane,
- 616 S. S.; Parab, A. R.; Flores, K.; Katemauswa, M.; Gosmanov, C.; Hayes, S. E.; Zhang, Y.;
- 617 Li, D.; Woelfel-Monsivais, C.; Sankaranarayanan, K.; McCall, L.-I. Mapping of Host-
- 618 Parasite-Microbiome Interactions Reveals Metabolic Determinants of Tropism and
- 619 Tolerance in Chagas Disease. *Science Advances*. 2020.
- 620 https://doi.org/10.1126/sciadv.aaz2015.
- 621 (43) Sumner, L. W.; Amberg, A.; Barrett, D.; Beale, M. H.; Beger, R.; Daykin, C. A.; Fan, T.
- 622 W.-M.; Fiehn, O.; Goodacre, R.; Griffin, J. L.; Hankemeier, T.; Hardy, N.; Harnly, J.;
- Higashi, R.; Kopka, J.; Lane, A. N.; Lindon, J. C.; Marriott, P.; Nicholls, A. W.; Reily, M.
- 624 D.; Thaden, J. J.; Viant, M. R. Proposed Minimum Reporting Standards for Chemical
- 625 Analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative
- 626 (MSI). *Metabolomics* **2007**, *3* (3), 211–221.
- 627 (44) Trypanosoma Cruzi Infection in Dogs along the US-Mexico Border: R0 Changes with
- 628 Vector Species Composition. *Epidemics* **2023**, *45*, 100723.
- 629 (45) Dunn, W. B.; Broadhurst, D.; Begley, P.; Zelena, E.; Francis-McIntyre, S.; Anderson, N.;
- Brown, M.; Knowles, J. D.; Halsall, A.; Haselden, J. N.; Nicholls, A. W.; Wilson, I. D.;
- 631 Kell, D. B.; Goodacre, R. Procedures for Large-Scale Metabolic Profiling of Serum and

- 632 Plasma Using Gas Chromatography and Liquid Chromatography Coupled to Mass
- 633 Spectrometry. *Nat. Protoc.* **2011**, *6* (7), 1060–1083.
- 634 (46) Pluskal, T.; Castillo, S.; Villar-Briones, A.; Orešič, M. MZmine 2: Modular Framework for
- 635 Processing, Visualizing, and Analyzing Mass Spectrometry-Based Molecular Profile Data.
- 636 *BMC Bioinformatics* **2010**, *11* (1), 1–11.
- 637 (47) Nothias, L.-F.; Petras, D.; Schmid, R.; Dührkop, K.; Rainer, J.; Sarvepalli, A.; Protsyuk, I.;
- 638 Ernst, M.; Tsugawa, H.; Fleischauer, M.; Aicheler, F.; Aksenov, A. A.; Alka, O.; Allard, P.-
- 639 M.; Barsch, A.; Cachet, X.; Caraballo-Rodriguez, A. M.; Da Silva, R. R.; Dang, T.; Garg,
- 640 N.; Gauglitz, J. M.; Gurevich, A.; Isaac, G.; Jarmusch, A. K.; Kameník, Z.; Kang, K. B.;
- 641 Kessler, N.; Koester, I.; Korf, A.; Le Gouellec, A.; Ludwig, M.; Martin H, C.; McCall, L.-I.;
- 642 McSayles, J.; Meyer, S. W.; Mohimani, H.; Morsy, M.; Moyne, O.; Neumann, S.;
- 643 Neuweger, H.; Nguyen, N. H.; Nothias-Esposito, M.; Paolini, J.; Phelan, V. V.; Pluskal, T.;
- 644 Quinn, R. A.; Rogers, S.; Shrestha, B.; Tripathi, A.; van der Hooft, J. J. J.; Vargas, F.;
- 645 Weldon, K. C.; Witting, M.; Yang, H.; Zhang, Z.; Zubeil, F.; Kohlbacher, O.; Böcker, S.;
- Alexandrov, T.; Bandeira, N.; Wang, M.; Dorrestein, P. C. Feature-Based Molecular
- 647 Networking in the GNPS Analysis Environment. *Nat. Methods* **2020**, *17* (9), 905–908.
- 648 (48) Lesani, M.; Gosmanov, C.; Paun, A.; Lewis, M. D.; McCall, L.-I. Impact of Visceral
- 649 Leishmaniasis on Local Organ Metabolism in Hamsters. *Metabolites* **2022**, *12* (9).
- 650 https://doi.org/10.3390/metabo12090802.
- 651 (49) Liebisch, G.; Fahy, E.; Aoki, J.; Dennis, E. A.; Durand, T.; Ejsing, C. S.; Fedorova, M.;
- 652 Feussner, I.; Griffiths, W. J.; Köfeler, H.; Merrill, A. H., Jr; Murphy, R. C.; O'Donnell, V.
- B.; Oskolkova, O.; Subramaniam, S.; Wakelam, M. J. O.; Spener, F. Update on LIPID
- 654 MAPS Classification, Nomenclature, and Shorthand Notation for MS-Derived Lipid

655 Structures. J. Lipid Res. 2020, 61 (12), 1539–1555.

- 656 (50) Liebisch, G.; Vizcaíno, J. A.; Köfeler, H.; Trötzmüller, M.; Griffiths, W. J.; Schmitz, G.;
- 657 Spener, F.; Wakelam, M. J. O. Shorthand Notation for Lipid Structures Derived from Mass
- 658 Spectrometry. J. Lipid Res. 2013, 54 (6), 1523–1530.
- 659 (51) Bolyen, E.; Rideout, J. R.; Dillon, M. R.; Bokulich, N. A.; Abnet, C. C.; Al-Ghalith, G. A.;
- 660 Alexander, H.; Alm, E. J.; Arumugam, M.; Asnicar, F.; Bai, Y.; Bisanz, J. E.; Bittinger, K.;
- Brejnrod, A.; Brislawn, C. J.; Brown, C. T.; Callahan, B. J.; Caraballo-Rodríguez, A. M.;
- 662 Chase, J.; Cope, E. K.; Da Silva, R.; Diener, C.; Dorrestein, P. C.; Douglas, G. M.; Durall,
- 663 D. M.; Duvallet, C.; Edwardson, C. F.; Ernst, M.; Estaki, M.; Fouquier, J.; Gauglitz, J. M.;
- Gibbons, S. M.; Gibson, D. L.; Gonzalez, A.; Gorlick, K.; Guo, J.; Hillmann, B.; Holmes,
- 665 S.; Holste, H.; Huttenhower, C.; Huttley, G. A.; Janssen, S.; Jarmusch, A. K.; Jiang, L.;
- 666 Kaehler, B. D.; Kang, K. B.; Keefe, C. R.; Keim, P.; Kelley, S. T.; Knights, D.; Koester, I.;
- 667 Kosciolek, T.; Kreps, J.; Langille, M. G. I.; Lee, J.; Ley, R.; Liu, Y.-X.; Loftfield, E.;
- 668 Lozupone, C.; Maher, M.; Marotz, C.; Martin, B. D.; McDonald, D.; McIver, L. J.; Melnik,
- A. V.; Metcalf, J. L.; Morgan, S. C.; Morton, J. T.; Naimey, A. T.; Navas-Molina, J. A.;
- 670 Nothias, L. F.; Orchanian, S. B.; Pearson, T.; Peoples, S. L.; Petras, D.; Preuss, M. L.;
- 671 Pruesse, E.; Rasmussen, L. B.; Rivers, A.; Robeson, M. S., 2nd; Rosenthal, P.; Segata, N.;
- 672 Shaffer, M.; Shiffer, A.; Sinha, R.; Song, S. J.; Spear, J. R.; Swafford, A. D.; Thompson, L.
- R.; Torres, P. J.; Trinh, P.; Tripathi, A.; Turnbaugh, P. J.; Ul-Hasan, S.; van der Hooft, J. J.
- J.; Vargas, F.; Vázquez-Baeza, Y.; Vogtmann, E.; von Hippel, M.; Walters, W.; Wan, Y.;
- Wang, M.; Warren, J.; Weber, K. C.; Williamson, C. H. D.; Willis, A. D.; Xu, Z. Z.;
- 676 Zaneveld, J. R.; Zhang, Y.; Zhu, Q.; Knight, R.; Caporaso, J. G. Reproducible, Interactive,
- 677 Scalable and Extensible Microbiome Data Science Using QIIME 2. *Nat. Biotechnol.* 2019,

- **678** *37* (8), 852–857.
- 679 (52) Vázquez-Baeza, Y.; Pirrung, M.; Gonzalez, A.; Knight, R. EMPeror: A Tool for Visualizing
- 680 High-Throughput Microbial Community Data. *Gigascience* **2013**, *2* (1), 16.